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ABSTRACT
Adrenal hypoplasia congenita (AHC) can occur due to
deletions or mutations in the DAX 1 (NR0B1) gene on the
X chromosome (OMIM 300200). This form of AHC is
therefore predominantly seen in boys. Deletion of the DAX
1 gene can also be part of a larger contiguous deletion
including the centromeric dystrophin and glycerol kinase
(GK) genes. We report a girl with a de novo deletion at
Xp21.2 on the maternal chromosome, including DAX1, the
GK gene and 39 end of the dystrophin gene, who
presented with salt losing adrenal insufficiency and
moderate developmental delay, but relatively mild
features of muscular dystrophy. Investigation using the
androgen receptor as a marker gene identified skewed
inactivation of the X chromosome. In the patient’s
leucocytes, the paternal X chromosome was completely
inactive, but in muscle 20% of the active chromosomes
were of paternal origin. Thus skewed X inactivation
(deletion on the active maternal X chromosome with an
inactive paternal X chromosome) is associated with AHC
in a female. Variability in X inactivation between tissues
may account for the pronounced salt loss and adrenal
insufficiency but mild muscular dystrophy.
Adrenal hypoplasia congenita (AHC) is a disorder
of adrenal development resulting in primary
adrenal failure in early infancy or childhood. This
condition is inherited in two forms, either through
autosomal recessive inheritance—for example, due
to mutations in steriodogenic factor-1 (NR5A1)—
or more commonly through X-linked inheritance.
1–4
The X-linked form of AHC is due to a deletion or
mutation in the gene encoding DAX1 (NR0B1) and
is associated with hypogonadotropic hypogonad-
ism.
4 X-linked AHC may occur in isolation or as
part of a contiguous gene deletion syndrome at
Xp21 including genes for Duchenne muscular
dystrophy (DMD) and glycerol kinase deficiency
(GKD). Affected boys present with adrenal failure,
early muscle weakness, glyceroluria and delayed
development.
5–7 Occasionally loss of the telomeric
locus for IL1RAPL1 is also associated with devel-
opmental delay.
8
Rare cases of delayed puberty have been reported
in female carriers of DAX1 mutations, which are
postulated to be the result of non-random inacti-
vation of one X chromosome,
1 but detailed
molecular investigations have not been reported
and these women did not have any adrenal
features. We report the first case of a girl with salt
losing AHC, mild dystrophinopathy and GKD
associated with confirmed skewing of X inactiva-
tion of variable degree in different tissues.
SUBJECTS AND METHODS
Patient
A female child of unrelated white European
parents presented at 8 days of age with lethargy
and pyrexia, and was found to be hyponatraemic
(125 mmol/l) and hyperkalaemic (9.4 mmol/l). A
random cortisol was inappropriately low at
238 nmol/l and a synacthen test confirmed a low
basal cortisol value (105 nmol/l) rising to an
unsatisfactory peak of 420 nmol/l. The renin
concentration was elevated at .77 nmol/h/l (nor-
mal range 0.38–2 nmol/h/l (supine)), while the
aldosterone value was low at 80 pmol/l (normal
range 1000–6000 pmol/l). A subsequent adrenocor-
ticotrophic hormone (ACTH) concentration was
also high at .220 pmol/l (normal range 0–
10 pmol/l). She was commenced on hydrocorti-
sone, fludrocortisone and sodium supplements.
Her karyotype was confirmed as 46XX, and a
pelvic ultrasound demonstrated the presence of
normal internal female reproductive organs. Only
one adrenal gland was identified, probably as the
other gland was very poorly developed. Mutations
in the genes encoding steriodogenic acute regula-
tory protein (StAR) and steriodogenic factor 1 (SF-
1) were excluded.
From the age of 1 year there were concerns
about her development as she was failing to reach
her motor milestones and speech was delayed. At
the age of 20 months she was still unable to stand
and generalised hypotonia was present with
notably reduced reflexes. Creatinine kinase was
found to be very high at 8721 IU/L (normal value
25–180 IU/L). A muscle biopsy demonstrated a
significant abnormality in her dystrophin distribu-
tion, consistent with being a manifesting carrier of
muscular dystrophy. Dystrophin 1 was present in
most fibres, but dystrophins 2 and 3 were only
present in occasional fibres. In addition, increased
concentrations of glycerol were found on urine
organic acid analysis.
Her muscular dystrophy remained mild: at the
age of 7 years she is able to walk a reasonable
distance without difficulty, although she does
occasionally complain of pain in her calf muscles.
She is currently on hydrocortisone (10 mg/m
2/
day) and a relatively large dose of fludrocortisone
(250 mg/m
2/day) on which she remains well,
maintaining normal electrolytes and renin concen-
trations.
Molecular investigations
Fluorescent in situ hybridisation (FISH) was used
to determine the presence or absence of genes at
Xp21, and therefore define whether a contiguous
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DAX1 (NR0B1) probe (BAC RP11-1129A5), a GK probe (RP11-
229K14), and a dystrophin probe (NRM52), which shares
homology with exon 52 in the dystrophin gene. Using a dosage
test, the copy number of each of the 79 exons of the dystrophin
gene was measured to identify the extent of the deletion in the
dystrophin gene, using the P034 and P035 DMD multiplex
ligation dependent probe amplification kit from MRC-Holland.
Linkage analysis using marker DI671 situated in intron 67 of the
dystrophin gene was performed to identify the origin of the
deletion.
Glycerol kinase activity
Epstein–Barr virus (EBV) transformed leucocytes were grown in
RPMI 1640 with l-glutamine and 10% fetal calf serum, and
washed with phosphate buffered saline (PBS). Glycerol kinase
(GK) activity was measured in the cells after 2–3 min pre-
treatment by digitonin using the GK catalysed conversion of
[U-
14C]glycerol to [U-
14C]glycerol-3-phosphate as described
before.
9
Measurements were done in duplicates at two different
protein concentrations from 0.1–1.2 g/l. Protein determination
was performed on cell suspension dissolved in 0.5 mol/l NaOH
according to the method of Lowry.
10
Methylation status of the androgen receptor
Two DNA aliquots from each family member were digested
with restriction enzymes: one was HpaII, a methylation
sensitive enzyme; and the other was the methylation insensitive
enzyme, RsaI, which was used as a control for input DNA
(fig 1). The digests were boiled for 10 min to inactivate the
restriction enzymes and the products of digestion were used in
polymerase chain reactions (PCRs) to selectively amplify a
polymorphic CAG repeat within the androgen receptor (AR)
gene. The two AR alleles, which differ in size in mother and
father, were then visualised, sized and quantified using an ABI
3100 Genotyper (fig 2). The size of the allele indicates parental
origin and the area under the peak indicates the degree of
amplification of the allele.
HpaII digestion is blocked by methylation and therefore, in
females, only the active (unmethylated) copies of the X
chromosome are digested, and no PCR product is amplified.
Methylated AR sequence will be amplified by HpaII. These
digested copies do not amplify effectively, thus the PCR product
generated from an HpaII digested sample represents the
methylated (inactive) X chromosome.
The ratio of active (unmethylated) to inactive (methylated)
AR alleles is a measure of the degree of X inactivation.
11 This is
said to be skewed when the ratio of peaks differs significantly
from 50:50, generally by more than 70:30.
Hormone assays
Renin activity was measured using DiaSorin radioimmunoassay
(RIA) kit, (Saluggia, VC, Italy), and serum aldosterone values
were determined using an in house RIA (Leeds General
Infirmary, UK). ACTH and cortisol concentrations were
measured using a Siemens immunoassay (Immunolite 2000,
Llanberis, North Wales, UK).
RESULTS
FISH analysis confirmed the patient had a gene deletion
involving DAX-1 at Xp21.2, with a signal visible on only one X
chromosome (fig 3). FISH testing carried out on maternal
chromosomes showedthe presenceof two intactgenes suggesting
Figure 1 Method used to identify skewed X inactivation using two restriction enzymes (RsaI, which is methylation insensitive, and HpaII, which is
methylation sensitive) on DNA amplified from the androgen receptor gene, which contains a variable number of CAG repeats and allow identification of
parental DNA origin. AR, androgen receptor; PCR, polymerase chain reaction.
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gonadal mosaicism.FISHtesting using a GKprobe confirmed that
a signal was present on only one chromosome, indicating that the
GK gene was also deleted in the patient. The IL1RAPL1 locus
downstream of DAX-1 was intact in this individual indicating
that this was not the cause of her developmental delay.
Additional FISH studies using the dystrophin probe NRM52
demonstrated signals on both the patient’s X chromosomes,
implying that any deletion in the dystrophin gene had occurred
distal to exon 52.
Dosage analysis used to measure the copy number of each of
the 79 dystrophin exons confirmed that the deletion involved
exons 61 to 79, which would cause a DMD phenotype in males.
Linkage analysis, using marker DI671 situated in intron 67 of
the dystrophin gene and therefore within the region deleted in
the patient, was performed. Only one allele was detected in the
patient, corresponding to the paternal allele, confirming that
the de novo deletion was carried on her maternally inherited X
chromosome (fig 4).
Glycerol kinase activity
The level of GK activity was assessed in the proband’s EBV
transformed leucocytes compared to that in a normal control
and found to be ,1%, indicating complete inactivation of the
gene on the normal paternal allele.
X inactivation studies
Digestion with RsaI showed the proband had inherited a 270 bp
AR allele from her father and 273 bp allele from her mother
(fig 2). Digestion with HpaII showed that in the proband’s
leucocyte DNA the paternal X chromosome was completely
methylated (inactive), while the maternal chromosome, which
carries the contiguous gene deletion, was completely unmethy-
lated (active). In muscle there was a different pattern following
HpaII digestion with both paternal and maternal methylated
(inactive) alleles detected. The ratio of maternal to paternal
allele expression was estimated at 80:20, indicating partially
skewed X inactivation. Thus, in muscle approximately 20% of
the paternal X chromosome was active.
Figure 2 Genescanner traces for RsaI
and HpaII digestions of paternal, maternal
and proband DNA. A peak is produced for
each androgen receptor (AR) allele
amplified. The size of the allele is
determined by the number of repeats
within the AR gene. The area under the
peak indicates the degree of amplification
of that allele.
Figure 3 Fluorescent in situ
hybridisation (FISH) analysis
demonstrating deletion at Xp21.2. A
signal was visible on only one X
chromosome using probe 1129A5 (shown
as red). Two signals from the centromeric
X chromosome probe DXZ2 were visible
(shown as green).
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X-linked AHC is one of the most common causes of primary
adrenal failure in boys. While most cases are due to point
mutations in the DAX1 (NR0B1) gene, approximately one third
of cases are due to DAX1 deletions, often as part of a contiguous
gene deletion syndrome involving the dystrophin and GK genes.
DMD is caused by a deficiency in dystrophin, a membrane
associated protein found in muscle cells and neurones. This
results in progressive muscle weakness in childhood, together
with cardiomyopathy and respiratory problems. The signs of
GKD are highly variable, ranging from no obvious phenotype
with asymptomatic pseudohypertriglyceridaemia due to hyper-
glycerolaemia through to psychomotor retardation, growth
delay, bone dysplasia, hypoglycaemia, ketoacidosis and sei-
zures.
12 13 The signs of GKD in association with a contiguous
gene deletion syndrome can be difficult to separate from the
effects of the other conditions.
Thus routine screening for DMD (checking creatinine kinase
concentrations) and GKD (checking urine concentrations of
glycerol) should be carried out in any male presenting
neonatally with AHC, as clinical signs of these associated
disorders will not be apparent until later in infancy.
X-linked conditions, such as AHC, GKD and DMD, are
usually found only in males since females can express sufficient
levels of protein from the genes on their active X chromosome.
If AHC is diagnosed in a female, it is important to establish
whether there is a normal female karyotype, as females with
46XY karyotypes or Turner syndrome can manifest X-linked
conditions.
14–17 In the presence of a 46XX karyotype, autosomal
recessive causes of AHC (such as StAR, SF1, (NR5A1)
mutations) should be considered.
18 19
This case indicates the importance of considering X-linked
AHC in female patients. We have confirmed that the cause of
this girl’s adrenal insufficiency was due to a DAX1 deletion on
her maternal allele with skewed inactivation of her normal
paternal allele. Once X-linked AHC has been confirmed in any
patient, male or female, DMD and GKD should also be
considered. The difference in disease severity between AHC
and DMD in this child was due to the variability in the level of
inactivation of the X chromosome in different tissues. The
presence of functional dystrophin gene in muscle, albeit at 20%
of normal levels, has resulted in a relatively mild clinical
manifestation of DMD. At presentation, this child had notably
abnormal electrolytes consistent with severe salt wasting, but a
less severe deficiency of cortisol. Thus, mineralocorticoid
insufficiency may be the predominant presenting feature of X-
linked AHC, although glucocorticoid deficiency usually emerges
with time.
20 21
Although most female carriers of X-linked diseases are
asymptomatic, this is not always the case. Between 2.5–7.8%
of female carriers of dystrophin gene mutations have been
reported to have clinical symptoms.
22 23 The severity of
symptoms in female carriers varies from muscle pain and cramp
on exertion to severe muscle weakness leading to wheelchair
dependency.
24 Symptoms in carriers of DMD are usually
thought to be due to skewed X inactivation,
25 but they may
also be due to Turner syndrome or X-autosomal translocations
with a break point at Xp21 that disrupts the dystrophin gene
and is associated with preferential inactivation of the non-
translocated chromosome.
24 Differences in X inactivation
between tissues may also occur and result in dilated cardiomyo-
pathy in females without skeletal muscle weakness.
26 27
However, the relationship between clinical phenotype, dystro-
phin expression and degree of X inactivation is not simple
28;
female patients can present with muscular dystrophy and
normal X inactivation.
29
In this case, X inactivation studies in DNA derived from
peripheral blood mononuclear cells and from muscle tissue have
demonstrated differences in the degree of skewing between the
two tissues. There was no active paternally derived X
chromosome in blood, and presumably the adrenal gland, giving
rise to the neonatal presentation with salt losing adrenal failure.
However, as there was some function of her normal paternal X
chromosome in muscle, this patient had relatively mild signs of
DMD.
Skewed X inactivation may be due to primary stochastic or
genetic processes, or be secondary to cell selection during
development.
30 The initial choice of which X chromosome to
inactivate is thought to be random, with subsequent skewing
occurring as a consequence of post-inactivation selection against
cells in which the active X chromosome is abnormal.
31 This
phenomenon is observed in X:autosome translocations
32 and in
carriers of a number of X-linked disorders, such as ATRX
syndrome.
33 Positive selection for cells carrying a mutated active
X chromosome has also been reported.
34
The X inactivation process is controlled by the X inactivation
centre (Xic) on the proximal long arm of the X chromosome.
Mutations in the XIST gene at Xq13.2 have been reported to
cause familial non-random X chromosome inactivation. The
XIST locus has not been analysed in our patient, but does not lie
close to the deleted region. Other loci on the X chromosome
linked to familial skewing of X inactivation have been reported,
suggesting that these may be controlling the choice of X
chromosome in the inactivation process or subsequent survival
of cells during proliferation.
35 36
Skewed X inactivation occurring by chance appears to be rare,
but has been reported in a series of phenotypically normal
females. Skewing to the extent of .80:20 was observed in 8% of
cases and to .95:5 in 0.8% of cases.
37 There is no obvious
explanation for the skewed X inactivation in our case; this is
likely to represent a chance event as there is no apparent reason
for cells containing the mutated maternal X chromosome to be
positively selected during development. We did, however, find
differences in X inactivation between tissues. This infers that
the greater proportion of active paternal X chromosomes seen in
muscle compared to leucocytes may be due to a selection bias
against the maternal X chromosome.
Conclusion
A DAX1 mutation or deletion with skewed X inactivation
should be considered in the differential diagnosis in 46XX
females who present with neonatal adrenal insufficiency. Tests
to identify dystrophin and GK gene deletions should also be
undertaken to define whether a larger contiguous gene deletion
Figure 4 Linkage analysis in the parents
and proband using marker DI671 situated
in intron 67 of the dystrophin gene and
therefore within the area deleted in the
proband. Only one allele is detected in the
proband and this is equivalent in size to
her father’s marker at this locus,
confirming the deletion is carried on her
maternally inherited X chromosome.
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tissues in girls with a contiguous gene deletion syndrome may
account for differences in the severity of the disease manifesta-
tions.
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